Table 1. Patient demographics in the current era (1998–2011).
| PAK n = 488 |
PTA n = 321 |
SPK n = 306 |
Total n = 1115 |
|||||
|---|---|---|---|---|---|---|---|---|
| Recipient Factors | ||||||||
| Female | 227 | 46.5% | 202 | 62.9% | 125 | 40.8% | 554 | 49.6% |
| Age | 43.8 | ± 0.4 | 42.0 | ± 0.6 | 44.7 | ± 0.5 | 43.5 | ± 0.3 |
| BMI | 25.4 | ± 0.2 | 25.5 | ± 0.2 | 25.8 | ± 0.3 | 25.5 | ± 0.1 |
| <25 | 236 | 49.8% | 154 | 50.0% | 142 | 47.8% | 532 | 49.3% |
| 25–30 | 172 | 36.3% | 114 | 37.0% | 99 | 33.3% | 385 | 35.7% |
| >30 | 66 | 13.9% | 40 | 13.0% | 56 | 18.9% | 162 | 15.0% |
| Retransplant | 152 | 31.1% | 67 | 20.9% | 39 | 12.7% | 258 | 23.1% |
| History of Vascular Diseasea | 237 | 48.6% | 81 | 25.2% | 147 | 48.0% | 465 | 41.7% |
| Dialysisb | 260 | 57.5% | 40 | 13.4% | 201 | 76.1% | 501 | 49.4% |
| Smokerc | 56 | 12.1% | 36 | 13.8% | 34 | 11.1% | 126 | 12.2% |
| Donor Factors | ||||||||
| Female | 180 | 36.9% | 131 | 41.1% | 131 | 42.8% | 442 | 39.7% |
| Age | 29.1 | ± 0.6 | 27.7 | ± 0.7 | 33.1 | ± 0.8 | 29.8 | ± 0.4 |
| Race | ||||||||
| White | 414 | 93.2% | 271 | 92.2% | 250 | 95.1% | 935 | 93.4% |
| African American | 29 | 6.0% | 14 | 4.4% | 12 | 3.9% | 55 | 4.9% |
| Asian | 3 | 0.6% | 4 | 1.3% | 3 | 1.0% | 10 | 0.9% |
| Cause of Death | ||||||||
| Cerebrovascular Accident (Stroke) | 153 | 31.5% | 92 | 28.7% | 103 | 33.9% | 348 | 31.3% |
| Head Trauma or Gunshot Wound | 251 | 51.6% | 185 | 57.6% | 155 | 51.0% | 591 | 53.2% |
| Other | 84 | 17.3% | 44 | 13.7% | 63 | 20.6% | 176 | 15.8% |
| Social History | ||||||||
| Alcohol Abuse | 37 | 7.8% | 32 | 10.3% | 26 | 8.9% | 95 | 8.8% |
| Drug Abuse | 21 | 5.1% | 20 | 7.4% | 17 | 6.6% | 58 | 6.2% |
| Pancreatitis Donor | 2 | 0.8% | 2 | 0.7% | 1 | 0.3% | 5 | 0.5% |
| Donation After Cardiac Death | 7 | 1.4% | 12 | 3.8% | 13 | 4.2% | 32 | 2.9% |
| Body Mass Index | 24.8 | ± 0.2 | 24.3 | ± 0.3 | 25.1 | ± 0.3 | 24.7 | ± 0.1 |
| Elevated Recent Creatinine | 19 | 4.2% | 8 | 2.8% | 2 | 0.7% | 29 | 2.6% |
| Elevated Serum Amylase (>500) | 20 | 4.6% | 9 | 3.4% | 8 | 2.9% | 37 | 3.8% |
| Preservation Time in Hours | 17.3 | ± 0.2 | 17.3 | ± 0.3 | 17.4 | ± 0.3 | 17.3 | ± 0.1 |
| Interval Admission to Brain Death (Days) | 2.2 | ± 0.3 | 3.4 | ± 1.2 | 2.0 | ± 0.3 | 2.5 | ± 0.4 |
| Pancreas Donor Risk Index (pDRI) | 1.25 | ± 0.02 | 1.33 | ± 0.03 | 1.56 | ± 0.04 | 1.36 | ± 0.02 |
| Surgical Factors | ||||||||
| Bladder Drainage | 373 | 76.6% | 254 | 79.1% | 83 | 27.1% | 710 | 63.7% |
| Allosensitization | ||||||||
| Peak PRA Class I | 8.62 | ± 1.06 | 11.10 | ± 1.48 | 9.23 | ± 1.63 | 9.52 | ± 0.77 |
| Peak PRA Class II | 7.30 | ± 1.06 | 11.36 | ± 1.63 | 8.42 | ± 1.54 | 8.80 | ± 0.79 |
| Peak_Overall_PRA | 17.64 | ± 1.41 | 22.06 | ± 1.98 | 20.24 | ± 2.02 | 19.63 | ± 1.01 |
| Zero Mismatches | 8 | 1.7% | 12 | 3.8% | 45 | 14.8% | 65 | 5.9% |
| Peak PRA Greater than 80 | 47 | 9.7% | 46 | 14.4% | 50 | 16.5% | 143 | 12.9% |
| Immunosuppression | ||||||||
| Thymoglobulin or Atgam | 432 | 88.9% | 290 | 91.5% | 271 | 88.9% | 993 | 89.6% |
| Campath | 92 | 18.9% | 78 | 24.6% | 44 | 14.4% | 214 | 19.3% |
| IL-2R Monoclonal Antibody | 282 | 58.0% | 167 | 52.7% | 156 | 51.1% | 605 | 54.6% |
| Tacrolimus | 407 | 83.7% | 258 | 81.4% | 262 | 85.9% | 927 | 83.7% |
| Cyclosporine | 32 | 6.6% | 6 | 1.9% | 4 | 1.3% | 42 | 3.8% |
| MMF | 430 | 88.8% | 305 | 96.8% | 264 | 86.8% | 988 | 89.6% |
| Prednisone | 298 | 61.4% | 155 | 49.4% | 163 | 53.6% | 616 | 55.8% |
Count and Percent; or Mean ± S.E.M.